# Cresco Labs Joins Texas Medical Cannabis Program > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/texas-medical-cannabis-program-cresco-labs-license/ > **Published:** 2026-04-06T14:09:19-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:29:35-04:00 > **Clinical Summary:** Cresco Labs awarded a license in the Texas medical cannabis program, expanding access under strict low-THC regulations for qualifying patients. --- ✦ New CED Clinical Relevance  #84High Clinical Relevance  Strong evidence or policy relevance with direct clinical implications. ⚒ Cannabis News  |  CED Clinic PolicyAccessThcPtsdEpilepsy Why This Matters Texas operates one of the most restrictive [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) programs in the US, limiting access to low-THC products for a narrow range of conditions. Expansion of licensed operators may improve patient access to standardized products, though the clinical impact remains limited by the program’s restrictive qualifying conditions and THC caps. Clinical Summary Cresco Labs has been awarded a medical cannabis license in Texas, joining a small number of vertically integrated operators in the state’s Compassionate Use Program. Texas restricts medical cannabis to products containing no more than 1% THC by weight and limits qualifying conditions to specific diagnoses including epilepsy, autism, terminal cancer, and PTSD. The program requires physician registration and patient monitoring but does not allow flower products or higher-THC formulations available in other medical cannabis states. Dr. Caplan’s Take “For my Texas colleagues, this represents incremental progress in a challenging regulatory environment. The 1% THC limit significantly constrains our therapeutic options compared to other states, but having more licensed operators should improve product consistency and availability for qualifying patients.” Clinical Perspective 🧠 Clinicians in Texas should understand that this expansion doesn’t change the fundamental limitations of the state program — qualifying conditions remain narrow and THC limits restrictive. For patients with qualifying conditions, increased competition among operators may lead to better product quality and pricing, but therapeutic options remain limited compared to comprehensive medical cannabis programs. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Cresco%20Labs%20Awarded%20Texas%20Medical%20Cannabis%20License%20%40drcaplan&url=https%3A//www.cannabisbusinesstimes.com/us-states/texas/news/15821400/cresco-labs-awarded-texas-medical-cannabis-license)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.cannabisbusinesstimes.com/us-states/texas/news/15821400/cresco-labs-awarded-texas-medical-cannabis-license)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Cresco%20Labs%20Awarded%20Texas%20Medical%20Cannabis%20License%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.cannabisbusinesstimes.com/us-states/texas/news/15821400/cresco-labs-awarded-texas-medical-cannabis-license)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.cannabisbusinesstimes.com/us-states/texas/news/15821400/cresco-labs-awarded-texas-medical-cannabis-license](https://www.cannabisbusinesstimes.com/us-states/texas/news/15821400/cresco-labs-awarded-texas-medical-cannabis-license) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance rating of this cannabis news?](#What_is_the_clinical_relevance_rating_of_this_cannabis_news) - [What are the main topic areas covered in this cannabis policy update?](#What_are_the_main_topic_areas_covered_in_this_cannabis_policy_update) - [How does this relate to PTSD treatment?](#How_does_this_relate_to_PTSD_treatment) - [What does “high clinical relevance” mean for healthcare providers?](#What_does_8220high_clinical_relevance8221_mean_for_healthcare_providers) - [Are there specific THC policy changes discussed?](#Are_there_specific_THC_policy_changes_discussed) - [Related](#Related) ## FAQ #### What is the clinical relevance rating of this cannabis news? This article has been assigned CED Clinical Relevance #84 with “High Clinical Relevance” status. This indicates strong evidence or policy relevance with direct clinical implications for healthcare providers and patients. #### What are the main topic areas covered in this cannabis policy update? The article covers multiple key areas including policy changes, patient access issues, THC-related developments, and [PTSD treatment](https://cedclinic.com/cannabis-and-ptsd-treatment-memory-loss-benefits/) applications. These interconnected topics suggest comprehensive cannabis policy or regulatory updates. #### How does this relate to PTSD treatment? The article appears to address cannabis policy changes that may impact [PTSD treatment](https://cedclinic.com/cannabis-and-ptsd-treatment-memory-loss-benefits/) options. This could involve expanded access, new regulations, or clinical guidance for using [cannabis-based therapies](https://cedclinic.com/cannabinoids-inhibit-keratinocyte-proliferation-non-cb1-cb2/) in PTSD patients. #### What does “high clinical relevance” mean for healthcare providers? High clinical relevance indicates this information has direct, actionable implications for clinical practice. Healthcare providers should review these updates as they may affect patient care decisions, treatment protocols, or prescribing practices. #### Are there specific THC policy changes discussed? While the full article content isn’t visible, the THC tag suggests the policy updates involve tetrahydrocannabinol regulations or guidelines. This likely affects dosing, potency limits, or therapeutic applications of THC-containing cannabis products. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Alabama's medical cannabis program: Moving ahead, still hard to access – WSFA](https://cedclinic.com/alabama-medical-cannabis-access-challenges/) Explore challenges and progress in Alabama's medical cannabis program, highlighting access issues similar to Texas. [Read More](https://cedclinic.com/alabama-medical-cannabis-access-challenges/) [New York licenses five new medical marijuana companies – Times Union](https://cedclinic.com/new-york-medical-marijuana-program-expansion/) Learn how New York's expanding medical cannabis licenses compare to Texas' regulatory environment. [Discover More](https://cedclinic.com/new-york-medical-marijuana-program-expansion/) Trump eases regulation on state-licensed [medical marijuana](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) – USA Today Review federal regulatory changes affecting state [medical marijuana](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) programs, including Texas. Explore Details ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).